Deucrictibant
- Generic Name
- Deucrictibant
- Drug Type
- Small Molecule
- Chemical Formula
- C25H23ClF3N5O3
- CAS Number
- 2340111-58-0
- Unique Ingredient Identifier
- 69GCA2KX22
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Pharvaris Netherlands B.V.
- Target Recruit Count
- 130
- Registration Number
- NCT06679881
- Locations
- π¬π§
Study Site, London, United Kingdom
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Pharvaris Netherlands B.V.
- Target Recruit Count
- 81
- Registration Number
- NCT06669754
- Locations
- π¬π§
Study Site, Birmingham, United Kingdom
π¬π§Study site, Plymouth, United Kingdom
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Phase 2
- Conditions
- Hereditary AngioedemaHereditary Angioedema Type IHereditary Angioedema Types I and IIC1 Esterase Inhibitor [C1-INH] DeficiencyC1 Esterase Inhibitor DeficiencyHereditary Angioedema Type IIHereditary Angioedema - Type 2Hereditary Angioedema Type I and IIHereditary Angioedema AttackHereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Pharvaris Netherlands B.V.
- Target Recruit Count
- 140
- Registration Number
- NCT05396105
- Locations
- πΉπ·
Study site, Istanbul, Turkey
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Phase 2
Active, not recruiting
- Conditions
- Hereditary Angioedema Types I and IIHereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 2Hereditary AngioedemaHereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema AttackHereditary Angioedema - Type 1C1 Inhibitor DeficiencyC1 Esterase Inhibitor Deficiency
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pharvaris Netherlands B.V.
- Target Recruit Count
- 34
- Registration Number
- NCT05047185
- Locations
- π¦πΉ
Study Site, Wien, Austria
π¬π§Study site, Southampton, England, United Kingdom
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Phase 2
Completed
- Conditions
- Hereditary Angioedema - Type 1Hereditary AngioedemaHereditary Angioedema - Type 2Hereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema Types I and IIHereditary Angioedema AttackC1 Inhibitor DeficiencyHereditary Angioedema With C1 Esterase Inhibitor DeficiencyC1 Esterase Inhibitor Deficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Pharvaris Netherlands B.V.
- Target Recruit Count
- 74
- Registration Number
- NCT04618211
- Locations
- π¬π§
Study site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath